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ABSTRACT 
Chronic exposure to methamphetamine causes adaptive changes in brain, which underlie dependence 
symptoms. We have found that the transmembrane protein 168 (TMEM168) is overexpressed in the 
nucleus accumbens of mice upon repeated methamphetamine administration. Here, we firstly 
demonstrate the inhibitory effect of TMEM168 on methamphetamine-induced behavioral changes in 
mice, and attempt to elucidate the mechanism of this inhibition. We overexpressed TMEM168 in the 
nucleus accumbens of mice by using an adeno-associated virus vector (NAc-TMEM mice). 
Methamphetamine-induced hyperlocomotion and conditioned place preference were attenuated in 
NAc-TMEM mice. Additionally, methamphetamine-induced extracellular dopamine elevation was 
suppressed in the nucleus accumbens of NAc-TMEM mice. Next, we identified extracellular matrix 
protein osteopontin as an interacting partner of TMEM168, by conducting immunoprecipitation in 
cultured COS-7 cells. TMEM168 overexpression in COS-7 cells induced the enhancement of 
extracellular and intercellular osteopontin. Similarly, osteopontin enhancement was also observed in 
the nucleus accumbens of NAc-TMEM mice, in in vivo studies. Furthermore, the infusion of 
osteopontin proteins into the nucleus accumbens of mice was found to inhibit 
methamphetamine-induced hyperlocomotion and conditioned place preference. Our studies suggest 
that the TMEM168-regulated osteopontin system is a novel target pathway for the therapy of 
methamphetamine dependence, via regulating the dopaminergic function in the nucleus accumbens. 
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INTRODUCTION 
Methamphetamine (METH) dependence remains a serious social health problem in the world 
because of its association with addictive syndromes. Additionally, no effective therapeutic 
approaches have been identified to counter this dependence [1, 2]. Chronic METH exposure results 
in a neuropsychiatric disorder thought to be induced by adaptive changes at the molecular, cellular, 
and tissue levels, which are complex and often brain-region specific [3]. After repeated METH 
exposure, investigations on the adaptive changes in brain functions suggest that alterations in gene 
regulation contribute to the addictive phenotype in humans and animals. A variety of known 
molecules have been confirmed to be related to the genetic and behavioral changes resulting from 
psychostimulant addiction, such as brain-derived neurotrophic factor [4], nuclear factor-κB [5], 
ΔFosB [6], tumor necrosis factor-α [7], and tissue plasminogen activator [8]. However, the exact 
neuronal circuits and novel molecular cascades relevant to METH-related phenomena, remain to be 
investigated. 
The nucleus accumbens (NAc) is a key region of the reward system, which is very sensitive to 
the adaptive changes induced by stimulant exposure [9]. Thus, we investigated the accumbal 
mRNA expression changes after repeated METH administration for 6 days, using the previously 
described cDNA subtraction method [10]. We found that the mRNA expression of a novel molecule, 
the transmembrane protein 168 (TMEM168) (GenBank accession number NM_028990), 
significantly increased in the NAc. The TMEM168 protein has been analyzed to be consistent with 
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697 amino acid residues, including several putative transmembrane regions. Although the 
expression patterns of the tmem168 gene have been detected both in humans and mice [11], the 
neuronal function of TMEM168 protein has not been revealed as yet. tmem168 has been identified 
as a candidate gene of long-range epigenetic silencing regions in prostate cancer cells; however, 
few epigenetic differences have been detected between the normal group and the cancer group of 
cells [12]. tmem168 has been reported as one of the primary gene targets of transcription factor 
AP-2 gamma in hormone responsive breast carcinoma cells, although, its function is still unknown 
[13]. TMEM168 mRNA has been reported as a candidate target of age-related miRNA miR-125b in 
human dermal fibroblasts; however, the protein level of TMEM168 does not significantly alter with 
age [14]. Similarly, phosphotyrosine-dependent protein-protein interactions have been detected 
between TMEM168 and Crk-like proteins by the established yeast two-hybrid screening; however, 
the direct epitopes that mediate such these interactions are still unknown [15]. Moreover, 
TMEM168 has been identified as one of the molecule interacting with the extracellular matrix 
protein osteopontin (OPN) [16]; although, the specific functional relationship between TMEM168 
and OPN remains unclear. 
In this study, we overexpressed TMEM168 in the NAc of mice (NAc-TMEM mice) by using an 
adeno-associated virus (AAV) vector. Following this, we found that the increased TMEM168 
effectively attenuated METH-induced hyperlocomotion, conditioned place preference (CPP), and 
accumbal dopamine (DA) elevation. In order to further characterize the inhibitory mechanism of 
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TMEM168 overexpression on METH dependence, OPN was identified as an important modulator 
for TMEM168 to affect the reward circuitry in the NAc. Thus, we suggested a mechanistic linkage 
between TMEM168 and OPN to study METH dependence. 
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RESULTS 
Expression pattern of TMEM168 mRNA 
The expression of TMEM168 mRNA was detected in the individual organs (brain, heart, lung, 
stomach, liver, kidney, spleen, small intestine, testis, ovary, and uterus) of mice. The TMEM168 
mRNA was expressed highly in the brain compared to other organs (Fig. 1A). In situ hybridization 
analysis of sagittal brain sections indicated that TMEM168 mRNA expressed widely in the whole 
brain (Fig. 1B). The expression of TMEM168 mRNA was detected in the primary culture of neurons, 
astrocytes, and microglia. The TMEM168 mRNA was expressed highly in neurons compared to 
astrocytes and microglia. (Fig. 1C) 
 
Overexpression of TMEM168 mRNA in the NAc after METH administration and AAV vector 
microinjection 
After repeated administration with METH or saline for 6 days (2 mg/kg/day, s.c.), TMEM168 mRNA 
significantly increased in the NAc and hippocampus, compared to the saline administration group. The 
expression of accumbal TMEM168 mRNA revealed about 2.0 ± 1.0 folds compared to control (p < 
0.05) (Fig. 2A). The results of the in situ hybridization analysis showed that TMEM168 mRNA was 
obviously overexpressed around the AAV vector injection site in the NAc of NAc-TMEM mice (Fig. 
2B). Accumbal TMEM168 mRNA levels in NAc-TMEM mice increased 7.4 ± 0.18 folds, compared to 
that in NAc-Mock mice (p < 0.01) (Fig. 2C). 
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Inhibitory effects of the overexpressed accumbal TMEM168 on the METH-induced 
hyperlocomotion, and CPP 
Acute administration of METH (1 mg/kg, s.c.) induced an increase in the locomotor activity of 
NAc-Mock mice (p < 0.05); METH-induced hyperlocomotion was slightly but significantly attenuated 
in NAc-TMEM mice (p < 0.05, F(3,42)=48.33) (Fig. 3A). In the CPP paradigm, METH (1 mg/kg, s.c.) 
induced CPP in NAc-Mock mice (p < 0.01). However, METH-induced CPP was observed to be 
attenuated in NAc-TMEM mice (p < 0.05, F(3,64)=4.914) (Fig. 3B). These results indicated that 
METH-induced dependent behaviors were attenuated by TMEM168 overexpression. 
 
Inhibitory effects of the overexpressed accumbal TMEM168 on the METH-induced 
extracellular DA increases in the NAc 
The basal levels of accumbal extracellular DA in NAc-Mock and NAc-TMEM mice were analyzed by 
the in vivo microdialysis method. No significant differences between them were observed. After 
METH (1 mg/kg s.c.) administration, extracellular DA levels increased in NAc-Mock mice and these 
METH-induced increases were attenuated in NAc-TMEM mice (p < 0.05, F(1,10)=1.853) (Fig. 4A). 
Extracellular DA levels increased due to a high K+ (100 mM) stimulation in NAc-Mock mice. The 
elevated DA levels were also inhibited in the NAc-TMEM mice (p < 0.05, F(1,14)=7.141) (Fig. 4B). 
These results indicated a possible mechanism, that the DA release responses for neuronal activation in 
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the NAc were inhibited by TMEM168 overexpression, by which the pharmacological effect of METH 
was attenuated. 
 
TMEM168 expressed in the Golgi apparatus and increased extracellular OPN levels in COS-7 
cells 
CMV-flag-TMEM168 vector was transfected into COS-7 cells. To investigate the relationship of 
TMEM168 and OPN, the interaction between flag-TMEM168 and OPN was confirmed by 
immunoprecipitation (Fig. 5A). Moreover, both intercellular OPN protein levels (p < 0.05) (Fig. 5B) 
and extracellular OPN protein levels (p < 0.01) (Fig. 5C) were detected to be increased in COS-7 cells 
by the flag-TMEM168 transfection. Location of TMEM168 was detected by immunostaining. The 
result showed that TMEM168 expressed at one point beside the nucleus, which co-localized with the 
expression of Golgi marker Syntaxin 6 (Fig. 5D, 5E, 5F, 5G).  
 
OPN enhancement was induced by TMEM168 overexpression and attenuated METH responses 
We isolated the NAc tissues of NAc-TMEM mice by using the Percoll gradient analysis. The 
expression pattern of Syntaxin 6 (Golgi marker) and GAPDH (internal control) was similar to a 
previous study [17], which indicated that the Golgi apparatus-consisted fraction was isolated 
successfully from the NAc. The majority of TMEM168 and OPN were detected in this Syntaxin 
6-positive fraction, compared to other fractions (Fig. 6A). Total OPN protein levels in the NAc 
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increased about 1.5 ± 0.17 folds (p < 0.05) (Fig. 6B) in NAc-TMEM mice, compared to NAc-Mock 
mice. Furthermore, the bilateral intra-injection of OPN (0.03 μg/side) did not affect spontaneous 
locomotor activity in mice; however, METH-induced hyperlocomotion was attenuated in the OPN 
administration group, compared to the vehicle administration group (p < 0.05, F(3,16)=40.91) (Fig. 6C). 
Similarly, the bilateral intra-injection of OPN (0.03 μg/side) did not affect the place preference in 
mice; however, METH-induced CPP was attenuated in the OPN administration group, compared to the 
vehicle administration group (p < 0.05, F(3,26)=15.64) (Fig. 6D). 
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DISCUSSION 
Transcriptional studies on drug dependence reveal that alteration of gene expression is an important 
mechanism to induce adaptive changes in the brain, which underlie the regulation of behavioral 
abnormalities [18]. Since the NAc is one of the important regions in brain for the reward system [9], 
we investigated the molecules whose mRNA expression increased in the NAc after repeated METH 
administration in mice, by PCR-selected cDNA subtraction method. We found that TMEM168 
mRNA increased significantly in the NAc of the repeated administered mice. In this study, we 
demonstrated that TMEM168 regulated OPN system is a novel pathway to inhibit METH-induced 
behavior changes via regulating dopaminergic neuronal functions in the NAc. The overexpressed 
TMEM168 inhibited METH-induced hyperlocomotion and CPP. As the contribution of dopaminergic 
neurotransmission to those behaviors has been well documented [19], the attenuation on 
METH-induced DA elevation in the NAc-TMEM mice was consistent with the results of the present 
behavioral test. Therefore, our study suggests that TMEM168 can function as a METH-induced 
adaptive molecule, which acts to balance the neurotransmission after the toxic METH stimulation. 
Overexpression of TMEM168 by the AAV vector microinjection in the NAc decreases DA synaptic 
responses; following this, METH-induced hyperlocomotion and place preference get attenuated. 
Accumbal extracellular DA originates from the dopaminergic synapse terminal in the NAc, which 
projects from the ventral tegmental area [9, 20]. The AAV-vector-induced transduction should 
preferentially occur only in the local neurons, since the AAV-TMEM168 vector was injected into the 
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NAc [21, 22]. Thus, the AAV vector-induced TMEM168 overexpression would affect the functions 
of local neurons directly, and then the projected dopaminergic systems in the NAc would be affected 
via some accumbal extracellular media indirectly. The extracellular space between neuronal cells and 
the synaptic cleft is composed of an extracellular matrix (ECM) [23]. Previous evidences indicate 
that the ECM is an important regulator of neuronal plasticity and psychostimulant-induced addictive 
changes [24-26]. OPN is a member of the ECM family [27], and was reported as an interacting 
partner of TMEM168 [16]. In the present studies, the association between TMEM168 and OPN was 
confirmed by immunoprecipitation. Furthermore, extracellular and intercellular OPN increased in 
vitro in the flag-TMEM168-transfected COS-7 cells, and similarly accumbal OPN increased in vivo, 
in NAc-TMEM mice, respectively. Accordingly, OPN could be one candidate mediator for the 
TMEM168 overexpressed local cells to affect the projected dopaminergic terminal, which was 
related to the METH-induced behavioral changes. Moreover, intraaccumbal infusion of the OPN 
protein attenuated METH-induced hyperlocomotion and conditioned place preference, indicating that 
the elevated extracellular OPN in the NAc should participate in the inhibitory effect of TMEM168 on 
the METH-induced behavioral changes. 
The alternative translation of OPN mRNA generates two protein types, the intercellular form of OPN, 
and the secreted form of OPN [28]. Intercellular OPN remains inside the cells; alternatively, secreted 
extracellular type OPN is packaged in the Golgi apparatus, and then is transported into secretory 
vesicles, resulting in its secretion from the cells [28, 29]. The co-localization of TMEM168 and OPN 
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in the Golgi marker Syntaxin 6-consisted fraction was detected in the Percoll gradient analysis. Thus, 
OPN secretion should be increased by overexpressing TMEM168, via affecting the Golgi network 
process in the cells. 
According to related studies, two possibilities are presumed to clarify the downstream processes of 
the activated OPN signaling, related to drug exposure. One is that the integrin receptors might work 
as an OPN downstream pathway to control these addictive effects. Extracellular OPN interacts with 
αvβ1, αvβ3, αvβ5, and α8β1 integrin receptors via an arginine-glycine-aspartate (RGD) sequence 
present in the OPN protein [30]. The intraaccumbal injection of RGD peptide attenuates the relapse 
to cocaine-seeking behavior [31], and the expression of integrin β1 subunits decreases, as well as β3 
subunits increase in the NAc after cocaine administration [31, 32]. It is suggested that the 
RGD-integrin system is one parallel pathway, which underlies the inhibition of stimulant affection. 
Thus, the TMEM168-OPN pathway might influence the response of the reward system in the NAc 
via the RGD sequence, and integrin receptors. Furthermore, OPN is a member of the ECM family 
and it is cleaved by MMP-2,-3,-7 and -9, which results in structural and functional changes of the 
protein via the MMP-induced proteolytic breakdown [33-36]. Recently, MMP-2 and MMP-9 were 
reported to be required for the induction of behavioral changes in cocaine relapse and METH 
exposure, and reportedly mediate glutamatergic transient synaptic potentiation, and dopaminergic 
functions in the NAc [37-39]. Although the functional mechanism of MMPs in the NAc remains to 
be studied, our studies indicate a possibility that the TMEM168-regulated OPN system might 
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become a related event for the addictive effect of MMPs. 
It is an interesting result to find that extracellular OPN is related to DA-mediated METH-induced 
pharmacological action. Previous studies have indicated the relationship between OPN and the DA 
nigrostriatal pathway. OPN is elevated in the substantia nigra of the Parkinson's disease patients [40], 
and the interaction of OPN with integrin and CD44 receptors in the substantia nigra suggests a role 
in the neuroprotective effect in the Parkinson’s disease model animals [41]. However, no previous 
studies have indicated that OPN controls the dopaminergic mesolimbic pathway, which is involved 
in the reward system. As METH is an addictive and neurotoxic psychostimulant, the administration 
of METH can cause monoaminergic damage in humans and rodents such as neuroinflammation [42]. 
OPN is suggestive of a role in the endogenous neuroprotective action, such as anti-inflammatory 
actions and anti-oxidant actions after the toxic insults in the brain [41, 43-45]. In the present study, 
the accumbal TMEM168 was increased in the addictive models after repeated METH administration. 
Furthermore, when we overexpressed TMEM168 in the NAc of mice by using the AAV vector, OPN 
protein levels were elevated and the METH-induced addictive behaviors inhibited. Thus, the 
TMEM168 regulated OPN system may perform an adaptive mechanism, which protect to balance the 
adverse influences induced by METH. Although the relationship between TMEM168 and METH 
toxicity remains to be investigated, our group demonstrates that the overexpressed TMEM168 and 
OPN in the NAc can attenuate METH dependence. It should be noted that we cannot exclude the 
possibility of other parallel TMEM168-related pathways that underlie the inhibitory effect of 
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TMEM168 on METH-induced behavioral preferences; however, at least TMEM168 regulated OPN 
system has been proved to be one effective inhibitory mechanism on METH pharmacological 
actions. 
There are still some critical questions to be clarified in the future. What is the detailed mechanism for 
TMEM168 in the Golgi network process to increase extracellular OPN, and how does the TMEM168 
activated OPN downstream signaling pathway regulate extracellular DA in the NAc. Although the 
study of TMEM168 and OPN on drug dependence is still in an initial stage, we have found that 
TMEM168 overexpression actives the TMEM168-regulated OPN system, and then METH-induced 
pharmacological actions are attenuated by regulating the dopaminergic function in the NAc. Thus, 
our discoveries indicate that TMEM168 is a promising novel target for the therapy of METH 
dependence. 
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MATERIALS AND METHODS 
Animals and Drugs 
Male C57BL/6J mice (Nihon SLC, Inc. Hamamatsu, Japan) (8-week-old; 22–27 g) were housed in a 
room with a 12 h light/dark cycle (8 am–8 pm). All procedures followed the National Institute of 
Health Guideline for the Care and Use of Laboratory Animals and were approved by the Animal 
Experiments Committee of the University of Toyama (Permit Number A2015pha-21). METH was 
purchased from Dainippon Sumitomo Pharmaceutical Co. Ltd. (Osaka, Japan), and was dissolved in 
saline (0.1 mg/mL). Human osteopontin standard (R&D System, MN55413) was dissolved in saline 
at the concentration of 0.12 μg/μL. All other reagents were obtained from standard commercial 
sources. Each test was performed with different group of mice. 
 
AAV vector Production and Microinjection 
The production of the AAV vector has been described previously [46]. The AAV vector plasmids 
contained an expression cassette, consisting of a human cytomegalovirus immediate-early promoter, 
followed by cDNA encoding tmem168 (GenBank accession number NM_028990), and a simian 
virus 40 polyadenylation signal sequence.  
Mice were anesthetized with a combination anesthetic (medetomidine [0.3 mg/kg], midazolam [4.0 
mg/kg], and butorphanol [5.0 mg/kg]), and were fixed in a stereotactic frame (SR-5M, Narishige, 
Tokyo, Japan). AAV-TMEM168, or a mock vector (0.7 μl/side) suspension was injected bilaterally 
                                           
16 
 
into the NAc (1.5 mm anterior, and 0.8 mm lateral from bregma, 3.9 mm below the skull surface) 
[47] of mice (NAc-TMEM mice or NAc-Mock mice). The injection was carried out at 0.05 µL/min. 
Mice were used for experiments 3 weeks later.  
All procedures followed the Guideline for Recombinant DNA Experiment from the Ministry of 
education culture, sports, science and technology, Japan and were approved by the Gene 
Recombination Experiment Safety Committee of the University of Toyama (Permit Number 
G2015pha-21). 
 
Intra-accumbens injection procedures 
Intra-accumbens injection was performed according to previously described methods [31, 48, 49], 
with minor modifications. Mice were microinjected with OPN (0.03 μg) or PBS (vehicle) in a total 
volume of 0.25 μL/side at a rate of 0.25 μL/min using a microdrive pump (ESP-64; EICOM, Kyoto, 
Japan), and injectors were left in the NAc for an additional 30 sec to allow for diffusion after the 1 
min infusion period. 
 
Locomotor Activity tests 
Locomotor activity tests were performed according to a previously reported method [48]. Locomotor 
activity was measured for 1 hour immediately after the administration of METH (1 mg/kg, s.c.) or 
saline (s.c.), using digital counters with infrared sensors (Scanet MV-40; Melquest, Toyama, Japan). 
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Conditioned Place Preference (CPP) tests 
The CPP tests were performed according to a previously described method [48] with minor 
modifications. Time spent in each compartment was measured for 15 min using the light/dark mode 
of a Scanet MV-40 (Melquest) instrument on the preconditioning test day and the postconditioning 
test day. The CPP behaviors were expressed as Post–Pre values, which were calculated as [(post 
value) − (pre value)] to reflect the difference in time spent in METH and saline-conditioning sides in 
the post and pre-conditioning stages, respectively. 
 
In vivo microdialysis 
In vivo microdialysis was performed according to a previously described method [48]. Four hours 
after the probe was inserted, the baseline of DA levels was measured, which was the mean of the last 
three samples before METH administration (1 mg/kg) or high K⁺ -stimulation (100 mM). 
Chromatograms were controlled by an integrator (PowerChrom: AD Instruments, NSW, Australia) 
connected to a personal computer. 
 
In situ hybridization 
In situ hybridization was performed as previously reported methods [50]. Sagittal and coronal 
sections of the mouse whole brain were cut using a cryostat (20 μm thickness; Leica Biosystems, 
                                           
18 
 
Nussloch, Germany) and were treated with digoxigenin labeled TMEM168 antisense ribo-probes 
(accession number NM_028990; nucleotides 1697-2296) using standard protocols. The staining 
signal of the developed image was observed using an AxioObserver Z1 (Carl Zeiss, Jena, Germany). 
 
Quantitative real time RT-PCR analysis 
In the case of tissue mRNA detection, total RNA extraction from the mice tissues was carried out 
using the RNeasy Plus Mini Kit protocol (Qiagen, Tokyo, Japan). RNA (500 ng) from each tissue 
sample was transcribed into the cDNA using the Prime Script RT reagent kit (Takara, Kusatsu, 
Japan). Quantitative real time RT-PCR was run in a Thermal Cycler Dice Real Time System (Takara) 
using Power SYBR Green PCR Master Mix (Applied Biosystems, Foster, CA), with cDNA and gene 
specific primers (1 μM) following the manufacturer’s instructions. 36B4 transcript was used as the 
internal control. The primers of mouse TMEM168 used for real time RT-PCR were as follows: 
5'-GACAGAATCATGGCATCCAAAGG-3', and 5'-ATGGACTCCAGCGGCAAGACAA-3'.  The 
36B4 transcript amount was quantified using primers 5'-ACCCTGAAGTGCTCGACATC-3', and 
5'-AGGAAGGCCTTGACCTTTTC-3'. 
In the case of primary culture mRNA detection, the preparation of cultured rat primary neuron, 
cultured mice astrocyte and cultured microglia were described as previous methods [51-53]. Total 
RNA (500 ng) from each cells sample was transcribed into the cDNA and then the quantitative real 
time RT-PCR was run following the manufacturer’s instructions. β-actin transcript was used as the 
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internal control. The primers of rat TMEM168 used for real time RT-PCR were as follows: 
5'-CAGCCCACAAATGGAATCTT-3', and 5'-GCATTGAGCATGCCAGTAGA-3'. The β-actin 
transcript amount was quantified using primers 5'-TTCAACACCCCAGCCATGTA-3', and 
5'-GTGGTGGTGAAGCTGTAGCC-3'. 
 
Cell culture and transfection 
The experimental procedure was  conducted as described previously [54]. COS-7 cells were 
transfected with either the pCMV-flag-Mock vector, or the pCMV-flag-TMEM168 vector, using 
Lipofectamine 2000 (Invitrogen) for 24 h. 
 
Western blotting 
NAc tissues or COS-7 cells homogenates (10 μg total proteins) were separated using sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (10% poly-acrylamide) and blotted onto a polyvinylidene 
difluoride membrane. The membranes were incubated with primary antibodies against OPN (1:5000; 
DSHB, USA), Syntaxin 6 (1:1000; Cell Singaling, USA), TMEM168 (1:1000; Abcam, Japan), and 
GAPDH (1:5000; MBL, Japan) antibodies, overnight at 4°C. Following this, membranes were 
probed with anti-mouse or anti-rabbit immunoglobulin G, HRP-linked antibody (1:5000; GE 
Healthcore, UK) for 1 h at room temperature. The fluorescence of the protein band was detected by 
ImageQuant LAS4000mini (GE Healthcore). The immunoreactivity of western blots was quantified 
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by densitometry, using ImageJ software, and normalized to GAPDH. 
 
Isolation of Golgi 
Golgi in the NAc of mice were isolated by Percoll density gradient centrifugation, according to 
previously described methods [17, 28]. Briefly, the NAc tissues of four mice were minced by eight 
strokes in a glass homogenizer in ice-cold homogenizing buffer. Homogenates were centrifuged at 
150×g for 5 min (P1: the pellet), and supernatant was centrifuged at 1,500×g for 10 min. The pellet 
was suspended in homogenizing buffer containing 40% Percoll (GE Healthcore), and centrifuged at 
20,000×g for 20 min to obtain seven fractions from the top side to the bottom side, which were 
labeled by numbers from 7 to 1. The seven fractions were detected by western blotting, using the 15 
μL volume. 
 
Immunoprecipitation, ELISA analyses, and Immunostaining 
Co-immunoprecipitations of TMEM168-flag and OPN were carried out from total cell lysates in 300 
μL volume, which was centrifuged at 12,000×g for 10 min. Supernatant was incubated with 3 μL 
anti-flag antibody (Sigma-Aldrich Sigma) overnight at 4°C, then 60 μL of Protein G Sepharose Fast 
Flow (GE healthcare) were added, and incubation continued for another 3 hours. The pellet was 
washed 3 times and diluted in the sample buffer (62.5 mM Tris-HCl pH 6.8, 25% glycerol, 2% SDS, 
0.01% bromophenol blue, 350 mM dithiothreitol). The samples were analyzed by western blotting 
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with anti-OPN (1:5000; DSHB) antibody. 
To detect extracellular OPN, matrix metalloproteinase inhibitor batimastat (50 μl; Millipore, Billerica, 
MA) was added to the cell medium after vector transfection. Then the contents of OPN in the cell 
medium were analyzed using the Osteopontin Quantikine ELISA Kit (R&D Systems Inc., 
Minneapolis, MN), following the manufacturer’s instructions. 
The transfected COS-7 cells were fixed with 4% PFA for 15 min and permeabilized with 0.25% 
Triton X-100 for 15 min, followed by blocking in 10% goat serum for 1 h. The cells were incubated 
overnight with a primary antibody Syntaxin 6 (1: 50, Cell Signaling), and anti-flag (1:200, Sigma, 
Japan), at 4°C. The cells were subsequently incubated with CF488A anti-mouse goat IgG (1: 1000, 
Nacalai tesque) or Alexa Fluoro 594 anti- rabbit goat IgG (1: 1000, Nacalai tesque) for 2 h at room 
temperature. The sections were observed by an AxioObserver Z1 (Carl Zeiss). 
 
Statistical Analyses 
All data were expressed as mean ± standard error of the mean (S.E.M.). Statistical differences 
between the two groups were determined using a Student’s t test. Statistical differences among 
values for individual groups were determined by analysis of variance (ANOVA), followed by the 
Student–Newman–Keuls post-hoc tests when F ratios were significant (p < 0.05). To analyze the 
development of in vivo microdialysis, statistical differences were determined by ANOVA with 
repeated measurement, followed by Bonferroni’s post-hoc tests (Prism version 5). 
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Figure Legends 
 
Figure 1. Systemic and cerebral distribution of TMEM168 mRNA (A) TMEM168 mRNA highly 
expressed in mice brain, compared to other organs. Values are mean ± S.E.M.; n=3. (B) Sagittal 
section of the whole brain in mice was analyzed by in situ hybridization using TMEM168 sense 
(upper panel), and anti-sense probes (below panel). Same results were obtained by repeating the 
experiments 3 times, using 3 different mice. (C) TMEM168 mRNA expressed highly in primary 
cultured neurons, compared to primary cultured astrocytes and microglia. Values are mean ± S.E.M.; 
n=3. 
 
Figure 2. The relationship between TMEM168 and the pharmacological actions of METH in the 
naïve mice, and the AAV vector injected mice (A) Expression of TMEM168 mRNA was analyzed in 
various brain regions of mice after repeated saline and METH (2 mg/kg, s.c. for 6 days) 
administration. Values are mean ± S.E.M.; n=5; *p < 0.05 vs. saline group (Student-t test). PFC: 
prefrontal cortex, HIP: Hippocampus, STR: striatum, NAc: nucleus accumbens, TH: thalamus, CB: 
cerebellum. (B) The site of microinjection in NAc-TMEM mice and NAc-Mock mice was confirmed 
by in situ hybridization for TMEM168 mRNA. Upper panel and below panel indicate the results 
from NAc-TMEM mice and NAc-Mock mice, respectively. (C) TMEM168 mRNA levels in the 
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NAc-Mock mice and NAc-TMEM mice have been presented as relative to the expression of 36B4. 
Values are mean ± S.E.M.; n=10; **p < 0.01 vs. NAc-Mock (Student-t test).  
 
Figure 3. Inhibitory effect of TMEM168 on the METH-induced behavioral changes in NAc-TMEM 
mice compared to NAc-Mock mice (A) The locomotor activities in NAc-Mock mice and 
NAc-TMEM mice were measured for 60 min after METH administration (1 mg/kg, s.c.). Columns 
indicate means ± S.E.M.; n=9; *p < 0.05 vs NAc-Mock (saline), #p < 0.05 vs NAc-Mock (METH) 
(ANOVA followed by the Student–Newman–Keuls post-hoc tests). (B) NAc-Mock mice and 
NAc-TMEM mice were trained for place preference for METH. Place preference data were 
expressed as the proportion of time spent in the drug-paired conditioning compartment. Columns 
indicate means ± S.E.M.; n=11; **p < 0.01 vs NAc-Mock (saline); #p < 0.05 vs NAc-Mock (METH) 
(ANOVA followed by the Student–Newman–Keuls post-hoc tests). 
 
Figure 4. Effects of TMEM168 overexpression on METH and high K+-induced extracellular DA 
elevation in the NAc of NAc-Mock mice and NAc-TMEM mice (A) No differences of extracellular 
DA basal levels in the NAc were detected between NAc-Mock mice, and NAc-TMEM mice. 
Dynamic changes in extracellular DA levels in the NAc after METH administration (1 mg/kg, s.c.) 
were calculated as a percent of basal levels. Values are mean ± S.E.M.; n=8; *p < 0.05 vs. 
NAc-Mock mice (ANOVA with repeated measures followed by Bonferroni’s post-hoc test). (B) 
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Dynamic changes of extracellular DA levels in the NAc after high K+ stimulation (100 mM, 15 min) 
were calculated as a percent of basal levels. Values are mean ± S.E.M.; n=4; *p < 0.05 vs. 
NAc-Mock mice (ANOVA with repeated measures followed by the Bonferroni’s post-hoc test). 
 
Figure 5. TMEM168-induced the enhancement of OPN in vitro and the localization of the 
overexpressed TMEM168 in the COS-7 cells (A) Interaction between TMEM168 and OPN in the 
COS-7 cells, which were transfected with flag-TMEM168, was confirmed by 
co-immunoprecipitation. The experiments were done 3 times, and the same results were obtained. 
Full length blots are presented in Supplementary Figure S1. (B) Inductive effects of TMEM168 on 
the intercellular OPN expression in the COS-7 cells. GAPDH was used as an internal control. Date 
are expressed as mean ± S.E.M.; n=5; *p < 0.05 vs. Mock group (Student-t test). Full length blots are 
presented in Supplementary Figure S2. (C) Inductive effects of TMEM168 on the extracellular OPN 
expression in COS-7 cells. Levels of extracellular OPN were analyzed by ELISA. Results were 
normalized to the amount of media protein and expressed as OPN per milligram protein. Date are 
expressed as mean ± S.E.M.; n=8; **p < 0.01 vs. Mock group (Student-t test). Localization of 
flag-TMEM168 and Syntaxin 6 in COS-7 cells was detected by immunostaining. (D) Overlapped 
images with flag-TMEM168, Syntaxin 6, and DAPI. (E) flag-TMEM168. (F) Syntaxin 6. (G) DAPI.  
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Figure 6. Interaction with TMEM168 and OPN in the Golgi and the inhibitory effect of OPN on 
METH-induced behavioral changes (A) Co-expression of TMEM168 and OPN in the Golgi 
consisted of a fraction separated from four TMEM168 overexpressed NAc tissue, detected by the 
Percoll gradient analysis. The experiments were done 3 times and the same results were obtained. 
Full length blots are presented in Supplementary Figure S3. (B) Accumbal OPN expression in 
NAc-Mock mice and NAc-TMEM mice was detected by western blotting. GAPDH was used as an 
internal control. Date are expressed as mean ± S.E.M.; n=6; *p < 0.05 vs. NAc-Mock mice 
(Student-t test). Full length blots are presented in Supplementary Figure S4. (C) OPN protein (0.03 
μg/0.25 μL/side) was intra injected bilaterally before the administration of METH (1 mg/kg s.c) or 
saline (s.c.) and then locomotor activity tests were carried out immediately. The locomotor activity 
was measured for 60 min. Columns indicate means ±S.E.M.; n=5; *p < 0.05 vs vehicle (METH), #p 
< 0.05 vs vehicle (saline) (ANOVA followed by the Student–Newman–Keuls post-hoc tests). (D) In 
the conditioning process, OPN protein (0.03 μg/0.25 μL/side) was intra injected bilaterally before the 
administration of METH (1 mg/kg s.c) on the drug-paired compartment, and PBS (0.25 μL/side) was 
intra injected bilaterally before the administration of saline (s.c.) on the saline-paired compartment. 
Time spent in each compartment was measured for 15 min on the preconditioning test day and the 
postconditioning test day. Place preference data was expressed as the proportion of time spent in the 
drug-paired conditioning compartment. Columns indicate means ±S.E.M.; n=6-8; *p < 0.05 vs 
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vehicle (METH), #p < 0.05 vs vehicle (saline) (ANOVA followed by the Student–Newman–Keuls 
post-hoc tests). 
